WO2007112922A1 - Composés trimères d'aminopyrazole hydrosolubles à action contre des maladies neurodégénératives - Google Patents

Composés trimères d'aminopyrazole hydrosolubles à action contre des maladies neurodégénératives Download PDF

Info

Publication number
WO2007112922A1
WO2007112922A1 PCT/EP2007/002782 EP2007002782W WO2007112922A1 WO 2007112922 A1 WO2007112922 A1 WO 2007112922A1 EP 2007002782 W EP2007002782 W EP 2007002782W WO 2007112922 A1 WO2007112922 A1 WO 2007112922A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
aminopyrazole
soluble
water
formula
Prior art date
Application number
PCT/EP2007/002782
Other languages
German (de)
English (en)
Inventor
Thomas Schrader
Detlev Riesner
Luitgard Nagel-Steger
Frank Biesemeier
Katrin Hochdörffer
Original Assignee
Philipps-Universität Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philipps-Universität Marburg filed Critical Philipps-Universität Marburg
Publication of WO2007112922A1 publication Critical patent/WO2007112922A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Definitions

  • the invention relates to novel, non-peptide aminopyrazole-based active compounds and to processes for their preparation. These drugs are able to prevent the de novo aggregation of Alzheimer's peptide, prion protein, ⁇ -synuclein and huntingtin as well as to dissolve existing aggregates.
  • Alzheimer's disease which is associated with a serious impairment of cognitive abilities.
  • Neurobiological characteristics of Alzheimer's disease are the conversion of normal ⁇ -helical protein structures to abnormal ⁇ -sheet structures ( ⁇ -amyloid patches, ⁇ -AP), excessive loading of cytoskeletal ⁇ proteins with phosphate groups, and muscarinic degeneration, cholinergic neurons.
  • ß-AP are deposited between the nerve cells, so that the oxygen and energy supply of the brain is impaired and the nerve cells eventually die.
  • ⁇ proteins are normal components of the cytoskeleton.
  • acetylcholine esterase inhibitors which slow down and prevent the breakdown of acetylcholine.
  • phytotherapeutics cat's claw, St. John's wort, etc., as well as some non-steroidal anti-inflammatory drugs such as I-buprofen used, the mode of action of these preparations is unknown.
  • DE 102 21 052 A1 already describes heterocyclic active substances which bind to proteins or peptides having a ⁇ -sheet structure and are present at least as dimers.
  • the active substances mentioned there also contain amino pyrazole groups and can be used for the treatment, diagnosis and prophylaxis of diseases that are associated with the formation of a ⁇ -sheet structure and subsequent abnormal protein aggregation.
  • the interest in the active ingredients described there is considerable and has given rise to the search for further, pharmacologically interesting agents whose structures differ from those of DE 102 21 052 A1 and which are better than the previously known agents for dissolving pathogenic protein fibrils.
  • the invention therefore trimeric, water-soluble aminopyrazole compound of the formula I.
  • R 1 for H 1 is a straight-chain or branched alkyl group having up to 10 carbon atoms or an amino acid or polyamino acid residue
  • R 2 is an OH, OR 3 or NHR 3 group in which R 3 is a straight-chain or branched alkyl group 1 to 10 carbon atoms or an amino acid or polyamino acid residue.
  • R 3 is a straight-chain or branched alkyl group 1 to 10 carbon atoms or an amino acid or polyamino acid residue.
  • aminopyrazole derivatives according to the invention can be prepared by a surprisingly simple preparation process: the iterative coupling of ⁇ / -PMB-protected nitropyrazolecarboxylic esters with the aid of the coupling reagent PyClop followed by reduction of the nitro group with H 2 / Pd-C leads directly to oligomers, possibly after attachment of further solubility or affinity-mediating groups such as lysine building blocks be transferred by acidic deprotection in the finished active ingredients.
  • the manufacturing process used comprises the following steps:
  • the PMB-protected pyrazole component (with or without peptidically linked amino acid units) is treated with trifluoroacetic acid (about 1 mL per 0.01 g of compound to be deprotected). Optionally, it is largely dissolved in the ultrasonic bath. After 6-24 h at 60-70 0 C, the reaction mixture is cooled in an ice bath and mixed with the 5-10-fold volume of diethyl ether. The precipitate is collected by centrifugation, washed with a little diethyl ether and dried in an oil pump vacuum.
  • the active compounds according to the invention can be used for the treatment of Parkinson's disease, Alzheimer's disease and prion diseases and show their superior pharmacological properties in the following experiments:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention a pour objet des composés trimères d'aminopyrazole hydrosolubles de formule (I), dans laquelle R1 désigne H, un groupe alkyle à chaîne linéaire ou ramifiée renfermant jusqu'à 10 atomes de carbone, ou un reste aminoacide ou polyaminoacide, et R2 désigne un groupe OH, OR3 ou NHR3, dans lequel R3 désigne un groupe alkyle à chaîne linéaire ou ramifiée de 1 à 10 atomes de carbone, ou un reste aminoacide ou polyaminoacide.
PCT/EP2007/002782 2006-03-31 2007-03-29 Composés trimères d'aminopyrazole hydrosolubles à action contre des maladies neurodégénératives WO2007112922A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006015140.2 2006-03-31
DE102006015140A DE102006015140A1 (de) 2006-03-31 2006-03-31 Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen

Publications (1)

Publication Number Publication Date
WO2007112922A1 true WO2007112922A1 (fr) 2007-10-11

Family

ID=38328226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002782 WO2007112922A1 (fr) 2006-03-31 2007-03-29 Composés trimères d'aminopyrazole hydrosolubles à action contre des maladies neurodégénératives

Country Status (2)

Country Link
DE (1) DE102006015140A1 (fr)
WO (1) WO2007112922A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050864A1 (fr) 2009-10-26 2011-05-05 Universität Duisburg-Essen Nouveaux composés pour le traitement de maladies liées à un mauvais repliement de protéines
DE102010017130A1 (de) 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
US20120270795A1 (en) * 2009-10-26 2012-10-25 Thomas Schrader Compounds for the treatment of diseases related to protein misfolding

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3260865B1 (fr) 2012-04-05 2022-12-28 Priavoid GmbH Procédé de traitement du sang, produits sanguins et organes
JP6434903B2 (ja) 2012-04-05 2018-12-05 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
DE102012102998B4 (de) * 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
DE102014003262A1 (de) 2014-03-12 2015-09-17 Forschungszentrum Jülich GmbH Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
WO2015043567A1 (fr) 2013-09-26 2015-04-02 Forschungszentrum Jülich GmbH Peptides se liant aux bêta-amyloïdes et leur utilisation pour le traitement et le diagnostic de la maladie d'alzheimer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835659A1 (fr) * 1996-10-14 1998-04-15 Hoechst Marion Roussel Deutschland GmbH Utilisation d'antagonistes non peptidiques de la bradykinine dans la préparation de médicaments pour le traitement et la prévention de la maladie d'Alzheimer
WO2003095429A1 (fr) * 2002-05-10 2003-11-20 TransMIT Gesellschaft für Technologietransfer mbH Principes actifs utilises dans le traitement, le diagnostic et la prophylaxie de pathologies dans lesquelles interviennent des structures proteiques anormales
WO2004099155A2 (fr) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. Utilisation de derives de pyrazole substitues selectionnes et de composes associes en tant qu'antagonistes du recepteur b1 a la bradykinine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002239A1 (en) * 1999-12-29 2002-01-03 Tanaka Richard D. Binding of polyamides to proteins having SH3 or WW domains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835659A1 (fr) * 1996-10-14 1998-04-15 Hoechst Marion Roussel Deutschland GmbH Utilisation d'antagonistes non peptidiques de la bradykinine dans la préparation de médicaments pour le traitement et la prévention de la maladie d'Alzheimer
WO2003095429A1 (fr) * 2002-05-10 2003-11-20 TransMIT Gesellschaft für Technologietransfer mbH Principes actifs utilises dans le traitement, le diagnostic et la prophylaxie de pathologies dans lesquelles interviennent des structures proteiques anormales
WO2004099155A2 (fr) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. Utilisation de derives de pyrazole substitues selectionnes et de composes associes en tant qu'antagonistes du recepteur b1 a la bradykinine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RZEPECKI, PETRA ET AL: "Synthesis and Binding Studies of Alzheimer Ligands on Solid Support", JOURNAL OF ORGANIC CHEMISTRY , 72(10), 3614-3624 CODEN: JOCEAH; ISSN: 0022-3263, 2007, XP002446684 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050864A1 (fr) 2009-10-26 2011-05-05 Universität Duisburg-Essen Nouveaux composés pour le traitement de maladies liées à un mauvais repliement de protéines
US20120270795A1 (en) * 2009-10-26 2012-10-25 Thomas Schrader Compounds for the treatment of diseases related to protein misfolding
US8481494B2 (en) * 2009-10-26 2013-07-09 Thomas Schrader Compounds for the treatment of diseases related to protein misfolding
DE102010017130A1 (de) 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
WO2011147797A2 (fr) 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Composé hybride, son utilisation et son procédé de préparation
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
DE102006015140A1 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007112922A1 (fr) Composés trimères d'aminopyrazole hydrosolubles à action contre des maladies neurodégénératives
DE2714747A1 (de) Neue oxime der 7-aminothiazolylacetamidocephalosporansaeure, herstellungsverfahren, pharmazeutische zusammensetzungen und anwendung als arzneimittel
DE2713272A1 (de) Derivate der 7-aminothiazolyl-acetamido-cephalosporansaeure, ihr herstellungsverfahren sowie pharmazeutische zusammensetzungen
DE2742435A1 (de) Aminoalkylaether der peptide tetrahydro- sl 7810/f-ii, s 31794/f-1, aculeacin a und tetrahydroechinocandin b, ihre verwendung und herstellung
DE2442829A1 (de) Tetracyclische verbindungen und verfahren zu ihrer herstellung
DE60103394T2 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
EP0688789A1 (fr) Dérivés des lipopeptides, procédé de leur préparation et leur utilisation
CH633558A5 (de) Verfahren zur herstellung neuer cephalosporinderivate.
WO2001010845A1 (fr) Nouvelles diketo-piperazines
DD236522A5 (de) Verfahren zur herstellung medizinisch wertvoller verbindungen und zwischenverbindungen
WO1996017860A1 (fr) Nouveaux p-amidinobenzylamides dipeptidiques a restes n-terminaux sulfonyle ou aminosulfonyle
EP0058341A1 (fr) Dérivés de l'azépine, leur préparation et médicaments les contenant
DE2221912A1 (de) Penicillinester,deren Salze und Verfahren zu ihrer Herstellung
EP0133225A2 (fr) Dérivés de peptides et leurs sels, compositions pharmaceutiques les contenant, procédé et produits intermédiaires pour leur production
DE19845406C2 (de) Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2502296C2 (de) 1-N-(S)-3-Amino-2-hydroxypropionyl- und 1-N-(S)-4-Amino-2-hydroxybutyryl-substituierte 4,6-Di-(aminoglycosyl)-1,3-diaminocyclitole und deren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1117676B1 (fr) Derives de propanolamine reticules avec des acides galliques, utilises pour traiter des troubles du metabolisme lipidique
DE60003662T2 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE3130252A1 (de) 6-(5-((omega)-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydro-pyridazine und deren saeureadditionssalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE60014932T2 (de) Diazocindionderivate und ihre verwendung als tryptase inhibitoren
DE10155018A1 (de) Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
DE2737504A1 (de) Derivate der 3-carbamoyloxymethyl-7- aminothiazolyl-acetamido-cephalosporansaeure, ihr herstellungsverfahren sowie pharmazeutische zusammensetzungen
DE2917244A1 (de) 4'-substituierte 2,4-dichlor- alpha (imidazol-n-ylmethyl)-dibenzylaether, verfahren zu deren herstellung sowie solche enthaltende arzneimittel
DE69818051T2 (de) Neue N-(Benzolsulfonyl)-L-prolin-Verbindungen, Verfahren zu ihrer Herstellung und therapeutische Verwendung
CN106866792B (zh) 一类环十肽分子及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723726

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 07723726

Country of ref document: EP

Kind code of ref document: A1